Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Oct 27 2009

Fero Industries, Inc. (OTCBB: FROI) (the “Company”) is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc. As previously announced, the Company has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.

Alan M. Schechter, Chairman and CEO of Pyro Pharmaceuticals, Inc, was quoted as saying, “Pyro looks forward to completing the business combination with Fero Industries and pursuing its strategy of arresting bacterial growth by inhibiting specific metabolic pathways.”

Biochemical pathways govern the synthesis and metabolism of molecules required by all living organisms. Blocking a metabolic pathway by inhibiting one or more enzymes in a pathway can cause deleterious consequences for that organism, or a particular affliction, such as an inborn error in metabolism, or death. The inhibition of a pathway that ultimately results in the death of the organism is, a priori, inhibition of a pathway required for the survival of the organism and is termed an essential pathway. The inhibition of a pathway that does not result in the death of the organism can render that organism avirulent by affecting one or more processes that are required for pathogenesis.

Some biochemical pathways are identical from organism to organism. In other cases, mammals utilize a different pathway from disease causing organisms for the same or similar purpose. Pyro has realized that these distinctions can be used to develop methods for the rational design of drugs, specifically antibiotics. Identifying metabolic pathways that are unique and essential to disease causing microorganisms can be used as a method to develop novel therapeutics against disease causing species without causing harm to the mammalian organism.

Pyro has identified ten unique metabolic pathways in bacteria for which patents have been applied. Mr. Schechter commented, “Pyro’s pending patents reflect a number of important disease causing bacteria, protist, yeast, and fungal microorganisms in which an essential pathway is required for viability, including but not limited to the following bacteria causing diseases.” These include the causes of bubonic plague, certain urinary tract infections, malaria, chlamydia, influenza, leprosy, tuberculosis, cholera, dysentery, and cholera.